Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics ...

Ambry Genetics drives innovation in diagnostics by launching cutting-edge genetic tests and technologies. Its broad collaborations, novel research projects, and networks for data sharing ...

Myriad and its partners in the suit says that even though the patents on the natural genes are invalidated, Gene by Gene and Ambry Genetics are still in violation of 10 patents on the BRCA gene ...

Together, these studies represent a major step forward in variant classification, providing essential data that helps clinicians better assess cancer risks tied to genetic mutations. Ambry ...

“Such a high rate of a false positives in this particular study was unexpected,” says study coauthor Stephany Tandy-Connor of Ambry Genetics, in a statement. She notes that differences in testing ...

In Q3 2024, Tempus announced its intent to acquire Ambry Genetics in a deal valued at 15x EBITDA at $600mm, $375mm of which through cash and the remaining $225mm in equity. Ambry will expand ...

Financing was provided by Ares Management Credit funds. Ambry Genetics will continue operations as a wholly-owned subsidiary of Tempus under its current leadership team. Tempus is a technology ...

Ambry, a 25-year-old genetics testing firm, is expected to generate over $300 million in revenue this year, with growth boosted by market share gains following Invitae’s bankruptcy.